Literature DB >> 23932896

Circulating levels of soluble apoptosis-related molecules in patients with multiple sclerosis.

Montserrat Moreno1, Matías Sáenz-Cuesta, Joaquín Castilló, Ester Cantó, Laura Negrotto, Angela Vidal-Jordana, Xavier Montalban, Manuel Comabella.   

Abstract

Evidence exists that apoptotic elimination of autoreactive T lymphocytes is defective in multiple sclerosis (MS). Here, we measured serum levels of soluble forms of Fas (sFas), Fas ligand (sFasL) and TNF-related apoptosis-inducing ligand (sTRAIL) in 38 healthy controls (HC) and 92 untreated MS patients with different clinical forms and activity phases of the disease by immunoassay. Serum levels of sFas, sFasL and sTRAIL did not differ between MS patients and HC. sTRAIL levels were significantly decreased in RRMS during relapses. These findings support a role of TRAIL in the pathogenesis of MS, especially during the acute phases of the disease.
© 2013.

Entities:  

Keywords:  Apoptosis; Fas; FasL; Multiple sclerosis; Relapse; TRAIL

Mesh:

Substances:

Year:  2013        PMID: 23932896     DOI: 10.1016/j.jneuroim.2013.07.013

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  4 in total

1.  Adrenocorticotropic hormone versus methylprednisolone added to interferon β in patients with multiple sclerosis experiencing breakthrough disease: a randomized, rater-blinded trial.

Authors:  Regina Berkovich; Rohit Bakshi; Lilyana Amezcua; Robert C Axtell; Steven Y Cen; Shahamat Tauhid; Mohit Neema; Lawrence Steinman
Journal:  Ther Adv Neurol Disord       Date:  2016-10-19       Impact factor: 6.570

2.  Protein-Based Classifier to Predict Conversion from Clinically Isolated Syndrome to Multiple Sclerosis.

Authors:  Eva Borràs; Ester Cantó; Meena Choi; Luisa Maria Villar; José Carlos Álvarez-Cermeño; Cristina Chiva; Xavier Montalban; Olga Vitek; Manuel Comabella; Eduard Sabidó
Journal:  Mol Cell Proteomics       Date:  2015-11-09       Impact factor: 5.911

Review 3.  Clinical perspectives of TRAIL: insights into central nervous system disorders.

Authors:  Veronica Tisato; Arianna Gonelli; Rebecca Voltan; Paola Secchiero; Giorgio Zauli
Journal:  Cell Mol Life Sci       Date:  2016-02-24       Impact factor: 9.261

Review 4.  Insight into the divergent role of TRAIL in non-neoplastic neurological diseases.

Authors:  Shiqi Gao; Yuanjian Fang; Sheng Tu; Huaijun Chen; Anwen Shao
Journal:  J Cell Mol Med       Date:  2020-08-22       Impact factor: 5.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.